Khatun , M , Urpilainen , E , Ahtikoski , A , Arffman , R K , Pasanen , A , Puistola , U , Tapanainen , J S , Andersson , L C , Butzow , R , Loukovaara , M & Piltonen , T T 2021 , ' Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer ' , Pathology and Oncology Research , vol. 27 , 1609936 . https://doi.org/10.3389/pore.2021.1609936
Title: | Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer |
Author: | Khatun, Masuma; Urpilainen, Elina; Ahtikoski, Anne; Arffman, Riikka K.; Pasanen, Annukka; Puistola, Ulla; Tapanainen, Juha S.; Andersson, Leif C.; Butzow, Ralf; Loukovaara, Mikko; Piltonen, Terhi T. |
Contributor organization: | Department of Pathology University of Helsinki HUSLAB HUS Gynecology and Obstetrics Reproductive Disease Modeling Department of Obstetrics and Gynecology Clinicum Helsinki University Hospital Area Medicum |
Date: | 2021-09-28 |
Language: | eng |
Number of pages: | 9 |
Belongs to series: | Pathology and Oncology Research |
ISSN: | 1219-4956 |
DOI: | https://doi.org/10.3389/pore.2021.1609936 |
URI: | http://hdl.handle.net/10138/335887 |
Abstract: | Stanniocalcin-1 (STC-1) is a glycoprotein hormone involved in diverse biological processes, including regulation of calcium phosphate homeostasis, cell proliferation, apoptosis, inflammation, oxidative stress responses, and cancer development. The role of STC-1 in endometrial cancer (EC) is yet to be elucidated. In this study, we investigated the protein expression pattern of STC-1 in a tissue microarray (TMA) cohort of hysterectomy specimens from 832 patients with EC. We then evaluated the prognostic value of STC-1 expression regarding the clinicopathologic features and patients survival over a period of 140 months. Our results revealed that in EC tissue samples, STC-1 is mainly localized in the endometrial epithelium, although some expression was also observed in the stroma. Decreased STC-1 expression was associated with factors relating to a worse prognosis, such as grade 3 endometrioid tumors (p = 0.030), deep myometrial invasion (p = 0.003), lymphovascular space invasion (p = 0.050), and large tumor size (p = 0.001). Moreover, STC-1 expression was decreased in tumors obtained from obese women (p = 0.014) and in women with diabetes mellitus type 2 (DMT2; p = 0.001). Interestingly, the data also showed an association between DNA mismatch repair (MMR) deficiency and weak STC-1 expression, specifically in the endometrial epithelium (p = 0.048). No association was observed between STC-1 expression and disease-specific survival. As STC-1 expression was particularly low in cases with obesity and DMT2 in the TMA cohort, we also evaluated the correlation between metformin use and STC-1 expression in an additional EC cohort that only included women with DMT2 (n = 111). The analysis showed no difference in STC-1 expression in either the epithelium or the stroma in women undergoing metformin therapy compared to metformin non-users. Overall, our data may suggest a favorable role for STC-1 in EC behavior; however, further studies are required to elucidate the detailed mechanism and possible applications to cancer treatment. |
Description: | Publisher Copyright: © Copyright © 2021 Khatun, Urpilainen, Ahtikoski, Arffman, Pasanen, Puistola, Tapanainen, Andersson, Butzow, Loukovaara and Piltonen. |
Subject: |
3111 Biomedicine
disease-specific survival endometrioid carcinoma metformin stanniocalcin-1 type 2 diabetes mellitus uterine cancer METFORMIN CELLS BIOMARKER RENAL ISCHEMIA/REPERFUSION INJURY INVASION ELEVATED EXPRESSION GENE-EXPRESSION CARCINOMA 3123 Gynaecology and paediatrics |
Peer reviewed: | Yes |
Rights: | cc_by |
Usage restriction: | openAccess |
Self-archived version: | publishedVersion |
Total number of downloads: Loading...
Files | Size | Format | View |
---|---|---|---|
pore_27_1609936.pdf | 1.493Mb |
View/ |